TQB-6411

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameTQB-6411
Drug Alias NameTQB6411TQB-6411
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1Anti-Hepatocyte growth factor receptor
TargetsEpidermal growth factor receptor erbB1Hepatocyte growth factor receptor
Therapy Area/IndicationsLung NeoplasmsEsophageal NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsEsophageal Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A